Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Spironolactone in Patients With Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged over 18 years~* Hypertension (essential or secondary) managed in Sheffield Hypertension Clinic or general practice or both.~* Blood pressures not adequately controlled (systolic blood pressure (SBP) \>140 mmHg and/or diastolic blood pressure (DBP) \>85 mmHg in clinic and on ambulatory blood pressure monitoring) despite treatment with the maximum tolerated dose of three antihypertensive agents.~* Additional antihypertensive treatment deemed appropriate by the patients' doctor.~* Patients' current antihypertensive treatment includes a thiazide diuretic and at least one of a beta-blocker, angiotensin converting enzyme inhibitor or angiotensin II receptor antagonist.~Exclusion Criteria:~* Definite indication or contraindication for spironolactone~* Known Conn's syndrome (definite indication for spironolactone)~* Heart failure NYHA class III or IV (definite indication for spironolactone)~* Known hepatic failure or significant cirrhosis~* Known pregnancy or women planning pregnancy~* Women of child bearing potential not using adequate contraceptive methods~* Serum creatinine \> 221µmol/l~* Serum Potassium \> 5.0mmol/l~* Clinic blood pressure or daytime ambulatory blood pressure \>240/120

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).